Cargando…

A novel individualized strategy for cryoballoon catheter ablation in patients with paroxysmal atrial fibrillation

BACKGROUND: The optimal dosage for cryoablation of atrial fibrillation (Cryo-AF) is still unknown. To evaluate the efficacy of an individualized freeze duration, we compared the clinical outcome of patients treated with a time-to-pulmonary vein isolation (TT-PVI) or temperature-guided ablation proto...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Jun, Xu, Jing, Ma, Wei, Chen, Bingwei, Yang, Peigen, Qi, Yu, Sun, Shan, Cheng, Aijuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6918665/
https://www.ncbi.nlm.nih.gov/pubmed/31847803
http://dx.doi.org/10.1186/s12872-019-01295-1
_version_ 1783480638170464256
author Ding, Jun
Xu, Jing
Ma, Wei
Chen, Bingwei
Yang, Peigen
Qi, Yu
Sun, Shan
Cheng, Aijuan
author_facet Ding, Jun
Xu, Jing
Ma, Wei
Chen, Bingwei
Yang, Peigen
Qi, Yu
Sun, Shan
Cheng, Aijuan
author_sort Ding, Jun
collection PubMed
description BACKGROUND: The optimal dosage for cryoablation of atrial fibrillation (Cryo-AF) is still unknown. To evaluate the efficacy of an individualized freeze duration, we compared the clinical outcome of patients treated with a time-to-pulmonary vein isolation (TT-PVI) or temperature-guided ablation protocol to the outcome of patients treated with a conventional ablation protocol. METHODS: A total of 164 consecutive patients were included in the study. One method employed was a conventional dosing protocol (at least 2 applications of 180 s each) (the Cryo-AF(Conventional) group n = 84), and the second method had a shorter protocol that was based on the TT-PVI or achievement of − 40 °C within 60 s (the Cryo-AF(Dosing) group n = 80) RESULTS: We treated 656 pulmonary veins (PVs) with 1420 cryotherapy applications. The mean number of applications per patient was 8.7 ± 0.8, with no difference between groups (Cryo-AF(Conventional), 8.7 ± 0.8 versus Cryo-AF(Dosing),8.6 ± 0.8; P = 0.359). The Cryo-AF(Dosing) group required significantly less total cryotherapy application time (990.60 ± 137.77versus 1501.58 ± 89.60 s; P < 0.001) and left atrial dwell time (69.91 ± 6.91 versus 86.48 ± 7.03 min; P < 0.001) than the Cryo-AF(Conventional) group. Additionally, the Cryo-AF(Dosing) group required significantly less total procedure time (95.03 ± 6.50 versus 112.43 ± 7.11 min; P < 0.001). We observed acute ATP-induced or spontaneous vein electric reconnections in 13 veins (1.98%) after 20 min. The reconnection rates between the Cryo-AF(Conventional) and Cryo-AF(Dosing) groups were similar in that 2.98 and 0.94% of the initially isolated veins were reconnected, respectively, (P = 0.061). There was no difference in the recurrence rate of free atrial arrhythmia after a 1-year follow-up, which were 78.75% in the Cryo-AF(Dosing) group versus 78.57% in the Cryo-AF(Conventional) group (P = 0.978). CONCLUSION: A novel Cryo-AF dosing protocol guided by temperature or the TT-PVI can be used to individualize an ablation strategy. This new protocol can lead to a significant reduction in duration of the procedure, the cryoenergy dosage and the left atrial dwell time. The procedure had equal safety and similar acute and 1-year follow-up outcomes compared to the conventional approach.
format Online
Article
Text
id pubmed-6918665
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-69186652019-12-20 A novel individualized strategy for cryoballoon catheter ablation in patients with paroxysmal atrial fibrillation Ding, Jun Xu, Jing Ma, Wei Chen, Bingwei Yang, Peigen Qi, Yu Sun, Shan Cheng, Aijuan BMC Cardiovasc Disord Research Article BACKGROUND: The optimal dosage for cryoablation of atrial fibrillation (Cryo-AF) is still unknown. To evaluate the efficacy of an individualized freeze duration, we compared the clinical outcome of patients treated with a time-to-pulmonary vein isolation (TT-PVI) or temperature-guided ablation protocol to the outcome of patients treated with a conventional ablation protocol. METHODS: A total of 164 consecutive patients were included in the study. One method employed was a conventional dosing protocol (at least 2 applications of 180 s each) (the Cryo-AF(Conventional) group n = 84), and the second method had a shorter protocol that was based on the TT-PVI or achievement of − 40 °C within 60 s (the Cryo-AF(Dosing) group n = 80) RESULTS: We treated 656 pulmonary veins (PVs) with 1420 cryotherapy applications. The mean number of applications per patient was 8.7 ± 0.8, with no difference between groups (Cryo-AF(Conventional), 8.7 ± 0.8 versus Cryo-AF(Dosing),8.6 ± 0.8; P = 0.359). The Cryo-AF(Dosing) group required significantly less total cryotherapy application time (990.60 ± 137.77versus 1501.58 ± 89.60 s; P < 0.001) and left atrial dwell time (69.91 ± 6.91 versus 86.48 ± 7.03 min; P < 0.001) than the Cryo-AF(Conventional) group. Additionally, the Cryo-AF(Dosing) group required significantly less total procedure time (95.03 ± 6.50 versus 112.43 ± 7.11 min; P < 0.001). We observed acute ATP-induced or spontaneous vein electric reconnections in 13 veins (1.98%) after 20 min. The reconnection rates between the Cryo-AF(Conventional) and Cryo-AF(Dosing) groups were similar in that 2.98 and 0.94% of the initially isolated veins were reconnected, respectively, (P = 0.061). There was no difference in the recurrence rate of free atrial arrhythmia after a 1-year follow-up, which were 78.75% in the Cryo-AF(Dosing) group versus 78.57% in the Cryo-AF(Conventional) group (P = 0.978). CONCLUSION: A novel Cryo-AF dosing protocol guided by temperature or the TT-PVI can be used to individualize an ablation strategy. This new protocol can lead to a significant reduction in duration of the procedure, the cryoenergy dosage and the left atrial dwell time. The procedure had equal safety and similar acute and 1-year follow-up outcomes compared to the conventional approach. BioMed Central 2019-12-17 /pmc/articles/PMC6918665/ /pubmed/31847803 http://dx.doi.org/10.1186/s12872-019-01295-1 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Ding, Jun
Xu, Jing
Ma, Wei
Chen, Bingwei
Yang, Peigen
Qi, Yu
Sun, Shan
Cheng, Aijuan
A novel individualized strategy for cryoballoon catheter ablation in patients with paroxysmal atrial fibrillation
title A novel individualized strategy for cryoballoon catheter ablation in patients with paroxysmal atrial fibrillation
title_full A novel individualized strategy for cryoballoon catheter ablation in patients with paroxysmal atrial fibrillation
title_fullStr A novel individualized strategy for cryoballoon catheter ablation in patients with paroxysmal atrial fibrillation
title_full_unstemmed A novel individualized strategy for cryoballoon catheter ablation in patients with paroxysmal atrial fibrillation
title_short A novel individualized strategy for cryoballoon catheter ablation in patients with paroxysmal atrial fibrillation
title_sort novel individualized strategy for cryoballoon catheter ablation in patients with paroxysmal atrial fibrillation
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6918665/
https://www.ncbi.nlm.nih.gov/pubmed/31847803
http://dx.doi.org/10.1186/s12872-019-01295-1
work_keys_str_mv AT dingjun anovelindividualizedstrategyforcryoballooncatheterablationinpatientswithparoxysmalatrialfibrillation
AT xujing anovelindividualizedstrategyforcryoballooncatheterablationinpatientswithparoxysmalatrialfibrillation
AT mawei anovelindividualizedstrategyforcryoballooncatheterablationinpatientswithparoxysmalatrialfibrillation
AT chenbingwei anovelindividualizedstrategyforcryoballooncatheterablationinpatientswithparoxysmalatrialfibrillation
AT yangpeigen anovelindividualizedstrategyforcryoballooncatheterablationinpatientswithparoxysmalatrialfibrillation
AT qiyu anovelindividualizedstrategyforcryoballooncatheterablationinpatientswithparoxysmalatrialfibrillation
AT sunshan anovelindividualizedstrategyforcryoballooncatheterablationinpatientswithparoxysmalatrialfibrillation
AT chengaijuan anovelindividualizedstrategyforcryoballooncatheterablationinpatientswithparoxysmalatrialfibrillation
AT dingjun novelindividualizedstrategyforcryoballooncatheterablationinpatientswithparoxysmalatrialfibrillation
AT xujing novelindividualizedstrategyforcryoballooncatheterablationinpatientswithparoxysmalatrialfibrillation
AT mawei novelindividualizedstrategyforcryoballooncatheterablationinpatientswithparoxysmalatrialfibrillation
AT chenbingwei novelindividualizedstrategyforcryoballooncatheterablationinpatientswithparoxysmalatrialfibrillation
AT yangpeigen novelindividualizedstrategyforcryoballooncatheterablationinpatientswithparoxysmalatrialfibrillation
AT qiyu novelindividualizedstrategyforcryoballooncatheterablationinpatientswithparoxysmalatrialfibrillation
AT sunshan novelindividualizedstrategyforcryoballooncatheterablationinpatientswithparoxysmalatrialfibrillation
AT chengaijuan novelindividualizedstrategyforcryoballooncatheterablationinpatientswithparoxysmalatrialfibrillation